Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation

American Journal of Kidney Diseases

Volumn 69, Issue 6, 2017, Pages 734-743

  Jun, Min ^a,b   James, Matthew T ^a,c   Ma, Zhihai ^a   Zhang, Jianguo ^a   Tonelli, Marcello ^a,c   McAlister, Finlay A ^d   Manns, Braden J ^a,c   Ravani, Pietro ^a,c   Quinn, Robert R ^a,c   Wiebe, Natasha ^d   Perkovic, Vlado ^b   Wilton, Stephen B ^c   Winkelmayer, Wolfgang C ^e   Hemmelgarn, Brenda R ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

antithrombotic therapy; Atrial fibrillation (AF); bleeding event; cardiovascular disease; chronic kidney disease (CKD); death; estimated glomerular filtration rate (eGFR); ischemic stroke; kidney function; major bleeding; stroke; transient ischemic attack (TIA); warfarin

Indexed keywords

CREATININE; WARFARIN; ANTICOAGULANT AGENT;

AGED; ALBERTA; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; EMERGENCY CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; ALBUMINURIA; CAUSE OF DEATH; CHEMICALLY INDUCED; COMORBIDITY; COMPARATIVE STUDY; COMPLICATION; ISCHEMIC ATTACK, TRANSIENT; METABOLISM; MORTALITY; RENAL INSUFFICIENCY, CHRONIC; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBERTA; ALBUMINURIA; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; CREATININE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MORTALITY; PROPENSITY SCORE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; STROKE; WARFARIN;

EID: 85008145212     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.10.018     Document Type: Article

References (38)

1. Chadban, S.J., Briganti, E.M., Kerr, P.G., et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 14:7 suppl 2 (2003), S131–S138.
2. Coresh, J., Astor, B.C., Greene, T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1 (2003), 1–12.
3. White, S.L., Polkinghorne, K.R., Atkins, R.C., et al. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 55:4 (2010), 660–670.
4. Herzog, C.A., Asinger, R.W., Berger, A.K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80:6 (2011), 572–586.
5. Seliger, S.L., Gillen, D.L., Longstreth, W.T. Jr., Kestenbaum, B., Stehman-Breen, C.O., Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 64:2 (2003), 603–609.
6. Alonso, A., Lopez, F.L., Matsushita, K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 123:25 (2011), 2946–2953.
7. Reinecke, H., Brand, E., Mesters, R., et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 20:4 (2009), 705–711.
8. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:12 (2007), 857–867.
9. Chan, K.E., Lazarus, J.M., Thadhani, R., et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20:10 (2009), 2223–2233.
10. Chan, K.E., Lazarus, J.M., Thadhani, R., et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20:4 (2009), 872–881.
11. Clase, C.M., Holden, R.M., Sood, M.M., et al. Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?. Nephrol Dial Transplant 27:10 (2012), 3719–3724.
12. Reynolds, J.L., Joannides, A.J., Skepper, J.N., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15:11 (2004), 2857–2867.
13. Hart, R.G., Pearce, L.A., Asinger, R.W., Herzog, C.A., Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 6:11 (2011), 2599–2604.
14. Carrero, J.J., Evans, M., Szummer, K., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 311:9 (2014), 919–928.
15. Olesen, J.B., Lip, G.Y., Kamper, A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:7 (2012), 625–635.
16. Shen, J.I., Montez-Rath, M.E., Lenihan, C.R., et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66:4 (2015), 677–688.
17. Shah, M., Tsadok, M.A., Jackevicius, C.A., et al. Warfarin use and the risk of stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129:11 (2014), 1196–1203.
18. Winkelmayer, W.C., Liu, J., Setoguchi, S., et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6:11 (2011), 2662–2668.
19. Wizemann, V., Tong, L., Satayathum, S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77:12 (2010), 1098–1106.
20. Fleet, J.L., Dixon, S.N., Shariff, S.Z., et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol, 14, 2013, 81.
21. Jensen, P.N., Johnson, K., Floyd, J., et al. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 21:suppl 1 (2012), 141–147.
22. Go, A.S., Fang, M.C., Udaltsova, N., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 119:10 (2009), 1363–1369.
23. Go, A.S., Hylek, E.M., Chang, Y., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 290:20 (2003), 2685–2692.
24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
25. Hux, J.E., Ivis, F., Flintoft, V., Bica, A., Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25:3 (2002), 512–516.
26. Quan, H., Khan, N., Hemmelgarn, B.R., et al. Validation of a case definition to define hypertension using administrative data. Hypertension 54:6 (2009), 1423–1428.
27. Gage, B.F., Waterman, A.D., Shannon, W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:22 (2001), 2864–2870.
28. Pisters, R., Lane, D.A., Nieuwlaat, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:5 (2010), 1093–1100.
29. Hemmelgarn, B.R., Manns, B.J., Lloyd, A., et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303:5 (2010), 423–429.
30. Jun, M., James, M.T., Manns, B.J., et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ, 350, 2015, h246.
31. Arnason, T., Wells, P.S., van Walraven, C., Forster, A.J., Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 118:2 (2006), 253–262.
32. Kokotailo, R.A., Hill, M.D., Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke 36:8 (2005), 1776–1781.
33. Austin, P.C., Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 134:5 (2007), 1128–1135.
34. Bonde, A.N., Lip, G.Y., Kamper, A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64:23 (2014), 2471–2482.
35. Friberg, L., Benson, L., Lip, G.Y., Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort Study. Eur Heart J 36:5 (2015), 297–306.
36. J-ROCKET Investigators. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 77:3 (2013), 632–638.
37. Hohnloser, S.H., Hijazi, Z., Thomas, L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:22 (2012), 2821–2830.
38. Quan, H., Sundararajan, V., Halfon, P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:11 (2005), 1130–1139.